Johnson & Johnson's MedTech Momentum Expected To Rebound In 2025 Despite Current Hurdles: Analyst

1. JNJ's Q4 adjusted EPS was $2.04, beating expectations. 2. Sales reached $22.52 billion, exceeding consensus estimates. 3. MedTech segment shows weaknesses amid competitive pressures. 4. M&A activity could drive long-term growth despite near-term struggles. 5. Talc litigation and pipeline drug trials may impact future performance.